For how we live.
Pooling 32 trials, researchers found milk, whey, casein, and soy protein lowered LDL and total cholesterol slightly — but the effect shrank once weaker studies were excluded.
One found PFAS mixtures associated with lower kidney filtration, with blood lipids mediating much of it. The other found the lipid association weaker in people with healthier habits.
Genetic and trial evidence establishes LDL as causal for atherosclerosis. The same kinds of evidence, applied to HDL, found that raising it does not lower heart attack risk.
A pooled analysis of 1.72 million people found no link between an egg a day and cardiovascular disease. A pooled analysis of six US cohorts found one. A randomised trial in 140 high-risk adults found neither.
Lipfendra cut LDL cholesterol by more than half in two trials. Its significance is less the number than the format: a once-daily tablet where every prior PCSK9 inhibitor required a needle.
Thirty-five people received VERVE-102 in a phase 1 trial. The edit is permanent, the follow-up is short, and the endpoint measured was cholesterol, not heart attacks.
The trial's own primary outcome — inflammation — was flat. What the new analysis adds is a molecular account of why the fat loss did not translate into the benefits fasting is sold on.